Advertisement

Topics

Roche's Tecentriq gets three years to prove itself on Cancer Drugs Fund

08:18 EDT 1 Nov 2017 | pharmaphorum

Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund. Overseen by England and Wales' cost effectiveness watchdog NIC...

Original Article: Roche's Tecentriq gets three years to prove itself on Cancer Drugs Fund

NEXT ARTICLE

More From BioPortfolio on "Roche's Tecentriq gets three years to prove itself on Cancer Drugs Fund"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...